Bradley Dixon, MD
Associate Professor, Pediatrics-Nephrology

Research Interests

Publications

• Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, Zhang Y, Li L. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep. 2023 Nov;8(11):2284-2293. PubMed PMID: 38025230
• Mitsnefes MM, Maltenfort M, Denburg MR, Flynn JT, Schuchard J, Dixon BP, Patel HP, Claes D, Dickinson K, Chen Y, Gluck C, Leonard M, Verghese PS, Forrest CB. Derivation of paediatric blood pressure percentiles from electronic health records. EBioMedicine. 2023 Dec;98:104885. PubMed PMID: 37988770
• Denburg MR, Razzaghi H, Goodwin Davies AJ, Dharnidharka V, Dixon BP, Flynn JT, Glenn D, Gluck CA, Harshman L, Jovanovska A, Katsoufis CP, Kratchman AL, Levondosky M, Levondosky R, McDonald J, Mitsnefes M, Modi ZJ, Musante J, Neu AM, Pan CG, Patel HP, Patterson LT, Schuchard J, Verghese PS, Wilson AC, Wong C, Forrest CB. The Preserving Kidney Function in Children With CKD (PRESERVE) Study: Rationale, Design, and Methods. Kidney Med. 2023 Nov;5(11):100722. PubMed PMID: 37965485
• Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 Sep;12(9):e230036. PubMed PMID: 37515502
• Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237. Kidney Int. 2023 Jul;104(1):205. PubMed PMID: 37349053
• Stone HK, Mitsnefes M, Dickinson K, Burrows EK, Razzaghi H, Luna IY, Gluck CA, Dixon BP, Dharnidharka VR, Smoyer WE, Somers MJ, Flynn JT, Furth SL, Bailey C, Forrest CB, Denburg M, Nehus E. Clinical course and management of children with IgA vasculitis with nephritis. Pediatr Nephrol. 2023 Nov;38(11):3721-3733. PubMed PMID: 37316676
• Stenson EK, Edelstein CL, You Z, Miyazaki-Anzai S, Thurman JM, Dixon BP, Zappitelli M, Goldstein SL, Akcan Arikan A, Kendrick J. Urine Complement Factor Ba Is Associated with AKI in Critically Ill Children. Kidney360. 2023 Mar 1;4(3):326-332. PubMed PMID: 36758197
• Gluck CA, Forrest CB, Davies AG, Maltenfort M, Mcdonald JR, Mitsnefes M, Dharnidharka VR, Dixon BP, Flynn JT, Somers MJ, Smoyer WE, Neu A, Hovinga CA, Skversky AL, Eissing T, Kaiser A, Breitenstein S, Furth SL, Denburg MR. Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):173-182. PubMed PMID: 36754006
• Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2023 May;38(5):1653-1665. PubMed PMID: 36251074
• Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 Jan;17(1):65-74. PubMed PMID: 34732529
• Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022 Nov 24;:1-14. [Epub ahead of print] PubMed PMID: 36423588
• Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022 Nov 18;:1-12. [Epub ahead of print] PubMed PMID: 36404708
• Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2022 Oct 17. [Epub ahead of print] PubMed PMID: 36251074
• Goodwin Davies AJ, Xiao R, Razzaghi H, Bailey LC, Utidjian L, Gluck C, Eckrich D, Dixon BP, Deakyne Davies SJ, Flynn JT, Ranade D, Smoyer WE, Kitzmiller M, Dharnidharka VR, Magnusen B, Mitsnefes M, Somers M, Claes DJ, Burrows EK, Luna IY, Furth SL, Forrest CB, Denburg MR. Skeletal Outcomes in Children and Young Adults with Glomerular Disease. J Am Soc Nephrol. 2022 Dec;33(12):2233-2246. PubMed PMID: 36171052
• Abu Jawdeh BG, Campos-Naciff B, Meganathan K, Steve Woodle E, Dixon BP. The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts. Transplant Direct. 2022 Sep;8(9):e1366. PubMed PMID: 35935026
• Chan M, Hanna MG, Willard N, Treece A, Dixon BP. Hypocomplementemic Atypical IgA Vasculitis: A Case Report. Front Pediatr. 2022;10:886371. PubMed PMID: 35757129
• Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul;47(7):1081-1087. PubMed PMID: 35304755
• Benoit SW, Fukuda T, VandenHeuvel K, Witte D, Fuller C, Willis J, Dixon BP, Drake KA. Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Front Pediatr. 2022;10:841051. PubMed PMID: 35281224
• Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 Jan;17(1):65-74. PubMed PMID: 34732529
• Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021 Jul;100(1):225-237. PubMed PMID: 33307104
• Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol. 2021 Feb;34(1):241-245. PubMed PMID: 32514992
• Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement activation fragments are increased in critically ill pediatric patients with severe acute kidney injury. Kidney360 Oct 2021, doi:10.34067/KID.0004542021.
• Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020 Dec 8. [Epub ahead of print] PubMed PMID: 33307104
• Marchbank KJ, Frazer-Abel A, Dragon-Durey MA, Dixon BP. Editorial: Autoantibodies in Kidney Diseases. Front Immunol. 2020;11:591338. PubMed PMID: 33042166
• Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol. 2020 Jun 8. [Epub ahead of print] PubMed PMID: 32514992
• Denburg MR, Razzaghi H, Bailey LC, Soranno DE, Pollack AH, Dharnidharka VR, Mitsnefes MM, Smoyer WE, Somers MJG, Zaritsky JJ, Flynn JT, Claes DJ, Dixon BP, Benton M, Mariani LH, Forrest CB, Furth SL. Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research. J Am Soc Nephrol. 2019 Dec;30(12):2427-2435. PubMed PMID: 31732612
• Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud. 2019;7:35-40. PubMed PMID: 31312592
• Kleene SJ, Siroky BJ, Landero-Figueroa JA, Dixon BP, Pachciarz NW, Lu L, Kleene NK. The TRPP2-dependent channel of renal primary cilia also requires TRPM3. PLoS One. 2019;14(3):e0214053. PubMed PMID: 30883612
• Benoit SW, Dixon BP, Goldstein SL, Bennett MR, Lane A, Lounder DT, Rotz SJ, Gloude NJ, Lake KE, Litts B, Davies SM. A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 Sep;54(9):1453-1461. PubMed PMID: 30700793
• Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2019 Feb;66(1):235-246. PubMed PMID: 30454746